News

Nous avons le plaisir de vous annoncer que l’intégration du logiciel ViroScore®-HIV (CE IVD) à la plateforme Nadis est bientôt disponible. Cette intégration va permettre à l’ensemble des utilisateurs Nadis de bénéficier de fonctionnalités avancées pour le génotypage du VIH telles que l…

ABL is pleased to announce the development and future release of the first version of MicrobioChek, a generic downstream analysis software intended to be used by microbiology laboratories for micro-organism related molecular analysis. Developed with the support of a RDI grant from the Ministry of th…

FLAGSTAFF, Ariz., LUXEMBOURG City, Luxembourg — In an important step toward eradicating tuberculosis (TB), the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories (ABL…

LUXEMBOURG VILLE, Luxembourg, and ROCHESTER, Minn. – Advanced Biological Laboratories (ABL), S.A., a Luxembourg-based diagnostics company and leader in virology genotyping, and Mayo Clinic Laboratories have announced a collaboration. The two organizations are working together to develop a clinical t…

ÉVRY, France and LUXEMBOURG City, Luxembourg (February 27th, 2019) – IntegraGen, a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, and Advanced Biological Laboratories (ABL), a leading integrated diagnostics…

ABL launches its Life Science division and starts the distribution of disruptive molecular biology instruments to be used for research purposes – Join our Early Access Program and get 30% discount on all UltraGene real time PCR systems! More information Join the program

Advanced Biological Laboratories (ABL) S.A. and ILC – Instrumentos de Laboratório e Científicos Lda are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Portugal. See current ch…

LUXEMBOURG VILLE, Luxembourg, December 27th, 2018 — Advanced Biological Laboratories (ABL) S.A. today announced the official launch of its Life Science division to provide on a worldwide basis, innovative solutions around molecular biology. It is also proud to announce the execution of a distr…

Advanced Biological Laboratories (ABL) S.A. and ELTA 90 Medical Science are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Serbia and Montenegro. See current channel partners.

New poster on HIV resistance to be presented at the HIV DART 2018 congress

We are pleased to announce that a new poster communication entitled “Clinical resistance to dolutegravir assessed by next-generation sequencing in patients pre-exposed to raltegravir” will be presented at the HIV DART and Emerging Viruses 2018 congress in Miami (USA, 27-29 November 2018)…

Advanced Biological Laboratories (ABL) S.A. and Bio-Active Co., Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand. See current channel partners.

ABL will be attending the next MEDICA forum in Dusseldorf from 12 – 15 November 2018: Hall 3 / B70 Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) Dee…

We are pleased to announce that, after 2015 and 2016, the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national quality control program in France, Switzerland and emerging countries (ANRS CQ 2017) through an independent lab and obtained 100% positive results on s…

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Illumina iSeq 100 Sequencing System. Download the technical note for more information.

ABL is pleased to announce the immediate availability of a new DeepChek® Assay intended to be used for Herpes Simplex Virus (HSV) genotyping and for determining the presence of mutations within UL23 (thymidine kinase) and UL30 (DNA polymerase) conferring drug resistance to antiviral drugs – DE…